Indivior (LON:INDV)‘s stock had its “buy” rating reissued by equities researchers at Numis Securities in a note issued to investors on Monday. They presently have a GBX 640 ($8.68) target price on the specialty pharmaceutical company’s stock. Numis Securities’ price objective would suggest a potential upside of 51.55% from the company’s previous close.

A number of other research firms have also commented on INDV. Morgan Stanley reissued an “equal weight” rating and issued a GBX 410 ($5.56) price target on shares of Indivior in a research report on Friday, December 1st. Citigroup raised shares of Indivior to a “buy” rating and boosted their target price for the stock from GBX 280 ($3.80) to GBX 490 ($6.64) in a research report on Wednesday, November 8th. Jefferies Group boosted their target price on shares of Indivior from GBX 358 ($4.85) to GBX 472 ($6.40) and gave the stock a “buy” rating in a research report on Thursday, November 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a GBX 500 ($6.78) target price on shares of Indivior in a research report on Friday, December 1st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Indivior has an average rating of “Buy” and a consensus target price of GBX 476.43 ($6.46).

Indivior (LON:INDV) opened at GBX 422.30 ($5.73) on Monday. Indivior has a 52-week low of GBX 246.50 ($3.34) and a 52-week high of GBX 436.60 ($5.92). The company has a market cap of $3,080.00 and a P/E ratio of 1,564.07.

WARNING: “Indivior (INDV) Rating Reiterated by Numis Securities” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2018/01/22/indivior-indv-rating-reiterated-by-numis-securities.html.

About Indivior

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.